NCT04550663Unknown1 期
One-center, Open-label, Single-arm Clinical Study of the Safety and Effectiveness of NKG2D CAR-T Cells Infusion in the Treatment of Relapsed/ Refractory NKG2DL+ Tumors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2020年9月25日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Maximum tolerated dose (MTD)
研究概览
简要总结
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.
详细描述
In this study,the enrollment of the patients must meet the inclusion and exclusion criteria . All subjects will be asked to continue to undergo long-term gene safety follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18, male & female;
- •Patients with recurrent/refractory NKG2DL+ tumors diagnosis by pathological histology or cytology, focus on the inclusion of patients with hepatocellular carcinoma positive. (If recruit liver cancer patients, patients should with locally advanced or metastatic hepatocellular carcinoma (HCC), Barcelona clinic liver cancer (BCLC) staging system classification for B or C, for B, patients are not suitable for local treatment and/or surgery, or disease progression occurs after surgery and/or local treatment, or declined to surgery and/or local treatment);
- •Patients who fail first-line treatment or are unwilling to receive first-line treatment;
- •Disease progression occurred within 14 days before inclusion (RECIST criteria must be used as a basis for assessment of disease progression). According to RECIST V1.1, patients have at least one measurable lesion. Target lesions located within the field of previous therapeutic irradiation or within the area of local treatment (interventional or ablative treatment) are considered measurable if progress is confirmed;
- •The main organs function normally and meet the following requirements;
- •Blood routine examination shall be in accordance with (no blood transfusion within 14 days) :
- •ANC ≥1.5×10^9/L
- •PLT ≥75×10^9/L
- •serum biochemicals examination shall be in accordance with:
- •BIL <1.5 upper normal limit (ULN)
- •ALT and AST<2.5×ULN; In the case of liver metastasis, ALT and AST<5×ULN
- •Serum Cr≤1×ULN, endogenous creatinine clearance≥50ml/min(Cockcroft-Gault formula)；
- •ECOG physical condition score: 0-1;
- •Expected survival time ≥3 months;
- •Cardiac function well before inclusion, no myocardial infarction attack occurred within half a year, and hypertension and other coronary heart disease were under control at present;
- •No other uncontrollable benign diseases such as lung, kidney, liver infection before enrollment;
- •Women of childbearing age must undergo a negative pregnancy test (serum or urine) within 7 days of enrollment and voluntarily use an appropriate method of contraception during observation and within 8 weeks after the last administration; men should be surgically sterilized or agree to use an appropriate method of contraception during the observation period and within 8 weeks after the last administration;
- •Patients voluntarily participated in this trial and sign the informed consent form;
- •Patients with compliance and expected to follow up the efficacy and adverse reactions as required by the protocol；
- •CAR-T cells amplify successfully to the expected number.
排除标准
- •Pregnant or lactating women, pregnancy test positive by blood or urine within 48 hours before immune cell transplantation;
- •Patients who need to be treated with systemic steroid;
- •Under following treatment conditions currently:
- •during the other anti-tumor clinical observation period within 14 days before blood collection;
- •patient has not recovered from acute side effects of the previous treatment;
- •Receive radiotherapy within 4 weeks before enrollment;
- •Patients who received any other cell therapy before;
- •Transfection efficiency of lymphocytes of patients < 5% in feasibility assessment screening stage, or T cell amplification efficiency < 5 times；
- •Uncontrolled symptoms or other illnesses, including but not limited to infection, congestive heart failure, unstable angina, arrhythmia, psychosis;
- •Patients with severe acute allergic reactions, or the attending doctor believes there is an unpredictable risk;
- •Patients who have received other cell therapies;
- •Other serious conditions that may limit patient's participation in the study.
研究组 & 干预措施
KD-025 CAR-T cells
Experimental
NKG2D-based CAR-T cells infusion
干预措施: KD-025 CAR-T cells (Drug)
结局指标
主要结局
Maximum tolerated dose (MTD)
时间窗: 90 days post infusion
Incidence of dose-limiting toxicities
The occurrence of AEs and SAEs during the study treatment
时间窗: 0 to 28 days post infusion
An adverse event is any undesirable experience associated with the use of a medical product in a patient
次要结局
- Progression free survival(PFS)(2 year post infusion)
- Overall survival (OS)(2 years post infusion)
- Objective remission rate(ORR)(1 year post infusion)
研究者
Baorui Liu
Professor of Medicine
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
研究点 (1)
Loading locations...
相似试验
招募中
不适用
NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid TumorsSafety IssuesNCT06509490Cancer Institute and Hospital, Chinese Academy of Medical Sciences9
招募中
1 期
NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid TumorPancreatic CancerSolid TumorGastric CancerNCT06134960Peking University12
招募中
早期 1 期
NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid TumorsSolid TumorPancreatic CancerGastric CancerNCT05583201jianming xu18
招募中
早期 1 期
NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid TumorsSolid TumorCRCNCT05382377jianming xu18
Unknown
1 期
Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung CancerNon Small Cell Lung CancerNCT04153799Sun Yat-sen University11